Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Inclusion criteria:

1. Voluntary and able to sign a dated ICF prior to any study-related procedures andable to complete the study as required by the protocol;

2. Aged ≥ 50 years at screening; Study Eye:

3. Diagnosis of nAMD as determined by the PI;

4. Active CNV lesions secondary to age-related macular degeneration (AMD);

5. Subjects must have been responsive to anti-VEGF therapy as assessed by the PI priorto study treatment.

Exclusion Criteria:

1. Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectiousblepharitis, uveitis) in the study eye at baseline;

2. Retinal pigment epithelial tear in the study eye at screening;

3. Current vitreous hemorrhage in the study eye or history of vitreous hemorrhagewithin 4 weeks prior to baseline;

4. Any condition that, in the opinion of the investigator, may limit visual acuityimprovement in the study eye;

5. History of retinal detachment or active retinal detachment in the study eye;

6. Any prior gene therapy.